Abstract: According to one embodiment, a modified piggyBac transposase polypeptide includes a piggyBac transposase amino acid sequence and a nuclear localization signal amino acid sequence.

Abstract: According to one embodiment, a substance delivery carrier and a composition are used for delivering an intended substance to a myeloid tumor cell. The substance delivery carrier has a lipid particle, and an intended substance encapsulated in the lipid particle. The lipid particle contains, as a constituent thereof, at least a first lipid represented by formula (I).

Abstract: According to one embodiment, a designing method for predicting a composition of a delivery carrier that satisfies a target value of an active agent delivery amount for a target cell is provided. The method includes preparing a delivery carrier prediction tool and acquiring, using the delivery carrier prediction tool, the composition of the delivery carrier that satisfies the target value based on a lipid composition of a cell membrane of the target cell.

Abstract: According to one embodiment, a method for manufacturing a lipid particle including a drug, the method includes cooling a solution containing the lipid particle including the drug at a rate of less than or equal to 1° C. per minute.

Abstract: A flow channel structure for removing a foreign substance includes a first flow channel, where the first flow channel has a first region having a depth shallower than a depth of another region. A method for removing a foreign substance in a fluid includes flowing the fluid to the first flow channel of the flow channel structure for removing a foreign substance.

Abstract: According to one embodiment, analytical methods and kits are provided for determining the probability that a subject has breast cancer, pancreatic cancer, lung cancer, gastric cancer, or colorectal cancer. The analytical methods include quantifying a target miRNA selected from a group of target miRNAs in a sample derived from the subject to be analyzed.

Abstract: According to one embodiment, a set of nucleic acid constructs which detects a DNA homologous recombination deficiency includes a first nucleic acid construct and a second nucleic acid construct. The first nucleic acid construct includes a first promoter sequence and a cleaved Cre gene ligated to downstream of the first promoter sequence. The second nucleic acid construct includes a second promoter sequence, a first loxP sequence ligated to downstream of the second promoter sequence, a reporter gene ligated to downstream of the first loxP sequence, and a second loxP sequence ligated to downstream of the reporter gene.

Abstract: According to one embodiment, a composition is for delivering an objective substance to the T-cell malignant tumor cell. The composition contains a substance delivery carrier. The substance delivery carrier has a lipid particle, and the objective substance encapsulated in the lipid particle. The lipid particle contains, as constituents thereof, at least a first lipid represented by formula (I) and a second lipid represented by formula (II).

Abstract: An information processing apparatus according to an embodiment includes a hardware processor connected to a memory. The hardware processor estimates a first disease incidence probability of a disease based on first information about expression levels of one or more types of biomarkers of a specimen. The hardware processor estimates a second disease incidence probability of a disease type based on the first information and the first disease incidence probability.

Abstract: According to one embodiment, a nucleic acid construct is used for detecting an estrogen-sensitive cell. The nucleic acid construct includes an enhancer sequence, a promoter sequence and a reporter gene. The enhancer sequence includes at least an ERE sequence and at least a XRE sequence. The promoter sequence is ligated to downstream of the enhancer sequence. The reporter gene is ligated to downstream of the promoter sequence.

Abstract: According to one embodiment, a therapeutic effect enhancer for promoting a therapeutic effect of a CAR-T cell therapy is provided. The therapeutic effect enhancer includes a nucleic acid that contains a gene encoding a target antigen of a CAR, and a nucleic acid that contains a gene encoding a costimulatory factor.

Abstract: A drug for genetic modification according to an embodiment is a drug for performing genome editing on a gene in a hematopoietic stem cell. The drug for genetic modification contains a genome editing molecule and a lipid nanoparticle encapsulating the genome editing molecule. The lipid nanoparticle includes a lipid membrane having a lumen. The lipid composition contains at least a first lipid (FFT-10) and a second lipid (FFT-20) in the lipid composition. The amount of the second lipid is larger than that of the first lipid, the total amount of the first lipid and the second lipid is 40 mol % or less, and the total amount of the cationic lipid is 60 mol % or less.

Abstract: According to one embodiment, a lipid particle for producing a CAR antigen-expressing cell derived from a CD209 positive cell is provided. The lipid particle includes a lipid membrane having a lumen, and a nucleic acid containing a CAR antigen gene being contained in the lumen.

Abstract: A sample identification method according to an embodiment includes setting a first reference sequence that includes a first sequence having a single base substitution site, the single base substitution site being a first base, and a corresponding second reference sequence, outputting the number of first short-chain nucleic acids having the first reference sequence and the number of second short-chain nucleic acids having the second reference sequence, calculating a ratio, obtaining a magnitude relationship between the ratio and a threshold value, and determining, from the number of sequences in which the ratio is greater than the threshold value, whether a subject from whom the sample is derived has the disease or at risk of developing the disease.

Abstract: According to one embodiment, an analysis method for determining a presence or absence of pancreatic cancer in a test subject, comprising quantifying corrective miRNA and target miRNAs in a sample derived from the test subject, wherein the target miRNAs are three or more selected from a group consisting of hsa-miR-205-5p, hsa-miR-223-5p, hsa-miR-29c-3p, hsa-miR-324-3p, hsa-miR-34a-5p, hsa-miR-483-5p and hsa-miR-885-5p.

Abstract: According to one embodiment, a radiotherapy lipid nanoparticle includes a biodegradable lipid nanoparticle, and a radioactive material as an active ingredient. The radioactive material is bound to the biodegradable lipid nanoparticle and located outside of the biodegradable lipid nanoparticle.

Abstract: According to one embodiment, there is provided a method of producing a gene modification T cell (CAR-T cells) which expresses a chimeric antigen receptor (CAR). This method includes stimulating a cell population containing a T cell with an antibody which activates the T cell, bringing the cell population into contact with a nucleic acid-introducing carrier, wherein the nucleic acid-introducing carrier containing a lipid particle, a first nucleic acid and containing a CAR gene, and a second nucleic acid containing a transposase gene encapsulated in the lipid particle, and culturing the cell population after the contacting.

Abstract: According to one embodiment, a particle-bound lipid nanoparticles includes a biodegradable lipid nanoparticle, a particle bound to an outer surface of the lipid nanoparticle, and an active substance bound to a surface of the particle.

Abstract: A flow path structure according to an embodiment includes three groups of flow paths connected by branch and merging portions. The first group connects to the second group via a branch portion, and the second group connects to the third group via a merging portion. The branch portion has openings on both the first and second group sides, while the merging portion has openings on both the second and third group sides. If the first group has N flow paths and the second group has M flow paths (where M is N or more), the total opening area of the second group's branch openings is at most M/N times that of the first group's branch openings. Additionally, at least one merging opening in the second group is equal to or smaller than at least one merging opening in the third group.

Abstract: According to one embodiment, a method is for maintaining and/or enhances the effect of an activator in a target cell. The method includes bringing a target cell in a first state into contact with a first lipid nanoparticle encapsulating a first activator, generating a target cell in a second state from the target cell in the first state, bringing a second lipid nanoparticle encapsulating a second activator into contact with the target cell in the second state, generating a target cell in a third state from the target cell in the second state, and maintaining and/or enhancing the effect of the activator in the target cell. Each of the first and second lipid nanoparticles is designed to exhibit an affinity appropriate for the corresponding target cell.